AstraZeneca says its $200M cash bet on Ionis’ ATTR drug is paying off — with PhIII data setting up FDA filing

When AstraZeneca wagered $200 million in cash upfront to bring in Ionis’ antisense candidate for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), it was not shy about introducing a potentially best-in-class drug in a space that, despite treatments from Alnylam, Pfizer and Ionis itself, still offers limited options. It now has the…

Click here to view original post